Skip to Main Content
Yale Cancer Center
YSM Home

INFORMATION FOR

Ovary, Phase III

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

What is the purpose of this trial?

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

  • Ages
    18 years - 99 years
  • Gender
    Female only
Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Rebecca Bartomeli

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sub-Investigators

  • Last Updated
    04/12/2026
  • Study IRB
    #2000040257

Contact Information

For more information about this study, including how to volunteer, contact Rebecca Bartomeli